Krsnaa Diagnostics Receives In-Principle Approval for Preferential Issue of Warrants
Krsnaa Diagnostics received in-principle approval from BSE and NSE for a preferential issue of 16,21,000 warrants to its Promoter and Promoter Group. Each warrant is convertible into one equity share at ₹566 per share. The approval was received on October 08, 2026.
The preferential issue of warrants to the promoter group is a significant corporate action that can impact shareholding patterns and potentially fund future growth, warranting a medium impact.
The company has received in-principle approval from stock exchanges for a preferential issue, which is a positive development for fundraising and strengthening the promoter's stake.
Krsnaa Diagnostics Limited has received in-principle approval from BSE Limited and the National Stock Exchange of India (NSE) for the preferential issue of 16,21,000 warrants convertible into equity shares.
The issue is to the Promoter and Promoter Group, with each warrant convertible into one equity share of face value ₹5 each at an issue price of ₹566 per share. This preferential issue is in accordance with Regulation 28(1) of SEBI (LODR) Regulations, 2015.
The company received the approval letters from the exchanges on October 08, 2026. While the NSE approval is complete, the BSE approval contains factual errors and will be re-submitted upon correction. The details of this approval will also be available on the company's website.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.